CureVac N.V.

As of September 30, 2025, CureVac N.V. has 225.17M shares outstanding.

As of September 30, 2025, CureVac N.V. trades at a trailing price-to-earnings ratio of 7.96. The price-to-sales ratio is 14.50, and the price-to-book ratio stands at -0.84.

As of September 30, 2025, CureVac N.V. trades at an EV/EBITDA multiple of 3.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. CureVac N.V. trades at an EV/FCF ratio of 4.32, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2025, CureVac N.V. maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.02, indicating elevated leverage, while an interest coverage ratio of 27.57 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2025. Return on invested capital (ROIC) comes in at 14.39 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -10.78, pointing to unprofitable operations over the period. Inventory turnover of 9.79 indicates how many times CureVac N.V. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended September 30, 2025. That works out to an effective tax rate of 18.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on January 6, 2026, CureVac N.V.'s stock has declined approximately 8.43% over the past 52 weeks. The 50-day moving average sits at 4.32, while the 200-day moving average is 4.14.

Over the twelve months ended September 30, 2025, CureVac N.V. posted a gross margin of 93.00, reflecting its pricing power and cost economics. The operating margin of 215.93 and net profit margin of 182.11 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2025. Free cash flow yield is negative at -11.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CureVac N.V. shareholders.

As of September 30, 2025, CureVac N.V. has an Altman Z-Score of 1.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.